Experimental lung cancer drug trial halted early
NCT ID NCT06186076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if the drug was safe and could shrink tumors. The trial was stopped early, and only 19 people took part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Chungbuk National University Hospital
Chungju, North Chungcheong, 28644, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam, Kyeongki, 13620, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
The Catholic University of Korea St. Vincent Hospital
Suwon, Kyeongki, 16247, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery